JP2016507502A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507502A5
JP2016507502A5 JP2015549756A JP2015549756A JP2016507502A5 JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5 JP 2015549756 A JP2015549756 A JP 2015549756A JP 2015549756 A JP2015549756 A JP 2015549756A JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclyl
carbocyclyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015549756A
Other languages
English (en)
Japanese (ja)
Other versions
JP6267231B2 (ja
JP2016507502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/076795 external-priority patent/WO2014100533A1/en
Publication of JP2016507502A publication Critical patent/JP2016507502A/ja
Publication of JP2016507502A5 publication Critical patent/JP2016507502A5/ja
Application granted granted Critical
Publication of JP6267231B2 publication Critical patent/JP6267231B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015549756A 2012-12-21 2013-12-20 カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール Expired - Fee Related JP6267231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740564P 2012-12-21 2012-12-21
US61/740,564 2012-12-21
PCT/US2013/076795 WO2014100533A1 (en) 2012-12-21 2013-12-20 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS

Publications (3)

Publication Number Publication Date
JP2016507502A JP2016507502A (ja) 2016-03-10
JP2016507502A5 true JP2016507502A5 (enExample) 2017-01-12
JP6267231B2 JP6267231B2 (ja) 2018-01-24

Family

ID=49943572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549756A Expired - Fee Related JP6267231B2 (ja) 2012-12-21 2013-12-20 カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール

Country Status (5)

Country Link
US (1) US9556179B2 (enExample)
EP (1) EP2935271B1 (enExample)
JP (1) JP6267231B2 (enExample)
CN (1) CN105073751B (enExample)
WO (1) WO2014100533A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
JP6564406B2 (ja) * 2014-06-19 2019-08-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
EP3221318B1 (en) * 2014-11-21 2021-08-25 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
JP6836998B2 (ja) * 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ, インコーポレイテッド TGF−β阻害剤
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
CA2994027C (en) 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
JP7177495B2 (ja) * 2016-09-21 2022-11-24 ベクタス・バイオシステムズ・リミテッド 高血圧症及び/又は線維症を処置するための組成物
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
ES2918448T3 (es) * 2018-03-29 2022-07-15 Univ Masarykova 4-(1H-Imidazol-5-il)-1H-pirrolo [2,3-b]piridinas para su uso en el tratamiento de leucemias, linfomas y tumores sólidos
AU2019336540B2 (en) * 2018-09-09 2025-02-13 Qanatpharma Ag Use of casein kinase 1 inhibitors for treating vascular diseases
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
AU2022225035A1 (en) 2021-02-24 2023-08-31 Insilico Medicine Ip Limited Analogs for the treatment of disease
WO2025231112A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof
WO2025231117A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2009137081A2 (en) 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
FR2940284B1 (fr) 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
MX2012004997A (es) 2009-10-28 2012-06-12 Pfizer Derivados de imidazol como inhibidores de la caseina quinasa.
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Similar Documents

Publication Publication Date Title
JP2016508135A5 (enExample)
JP2017518344A5 (enExample)
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
AU2018358157B2 (en) Modulators of the integrated stress pathway
ES2923875T3 (es) Moduladores de la vía integrada del estrés
JP2016537369A5 (enExample)
JP5576485B2 (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
JP2006524222A5 (enExample)
JP2017507122A5 (enExample)
CA3080808A1 (en) Modulators of the integrated stress pathway
JP2011525192A5 (enExample)
JP2018522866A5 (enExample)
JP2013528180A5 (enExample)
JP2009542716A5 (enExample)
JP2016503797A5 (enExample)
JP2015503609A5 (enExample)
JP2019535723A5 (enExample)
JP2013542267A5 (enExample)
JP2010527985A5 (enExample)
JP2013518036A5 (enExample)
JP2015522592A5 (enExample)
JP2014524449A5 (enExample)
ES2346323T3 (es) Bencimidazoles sustituidos y su uso para inducir apoptosis.
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用